Evidence mapPaperPMID 31959650Full record

ArticleDiabetes care2020

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.

Michael A Nauck, Eskil Kreiner, Søren Rasmussen, Hans A Saevereid, John B Buse, LEADER Trial Investigators

Abstract readLetterComment
In one paragraph

Article in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Michael A NauckDiabetes Division, St. Josef-Hospital (Ruhr University), Bochum, Germany michael.nauck@rub.de.ORCID 0000-0002-5749-6954
Eskil KreinerNovo Nordisk A/S, Søborg, Denmark.
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark.
Hans A SaevereidNovo Nordisk A/S, Søborg, Denmark.
John B Buse
LEADER Trial Investigators

Funding

Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
RADIANT Clinic and Data Coordinating CenterU54DK118612 · NIDDK · UNIVERSITY OF CHICAGO · 2022 to 2025
$8.2M
NCATS NIH HHS UL1 TR002489NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U54 DK118612NIDDK NIH HHS UC4 DK108612
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2GallbladderHumansHypoglycemic AgentsLiraglutideHypoglycemic AgentsLiraglutide

Identifiers

PMID31959650
PMCPMC7411284

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.